Thermo Fisher Scientific Inc. (TMO) Stake Lessened by Rothschild Investment Corp IL

Rothschild Investment Corp IL lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,855 shares of the medical research company’s stock after selling 4,032 shares during the period. Thermo Fisher Scientific accounts for about 1.5% of Rothschild Investment Corp IL’s investment portfolio, making the stock its 10th largest position. Rothschild Investment Corp IL’s holdings in Thermo Fisher Scientific were worth $13,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 2.0% in the first quarter. Valeo Financial Advisors LLC now owns 1,911 shares of the medical research company’s stock valued at $523,000 after purchasing an additional 38 shares in the last quarter. Archford Capital Strategies LLC grew its holdings in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Archford Capital Strategies LLC now owns 4,610 shares of the medical research company’s stock valued at $1,032,000 after purchasing an additional 43 shares in the last quarter. Aries Wealth Management grew its holdings in shares of Thermo Fisher Scientific by 1.1% in the fourth quarter. Aries Wealth Management now owns 4,269 shares of the medical research company’s stock valued at $955,000 after purchasing an additional 45 shares in the last quarter. Balasa Dinverno & Foltz LLC grew its holdings in shares of Thermo Fisher Scientific by 2.1% in the fourth quarter. Balasa Dinverno & Foltz LLC now owns 2,238 shares of the medical research company’s stock valued at $501,000 after purchasing an additional 46 shares in the last quarter. Finally, Atlas Capital Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 5.5% in the fourth quarter. Atlas Capital Advisors LLC now owns 923 shares of the medical research company’s stock valued at $207,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 88.66% of the company’s stock.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 target price for the company in a report on Tuesday, April 9th. Robert W. Baird lifted their price objective on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 30th. BTIG Research lifted their price objective on shares of Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Needham & Company LLC assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price objective for the company. Finally, Deutsche Bank lifted their price objective on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $289.92.

In other news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $266.00, for a total transaction of $665,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Gregory J. Herrema sold 5,400 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the sale, the senior vice president now directly owns 31,846 shares of the company’s stock, valued at $8,009,587.46. The disclosure for this sale can be found here. Insiders have sold 36,927 shares of company stock valued at $9,388,124 over the last three months. Insiders own 0.49% of the company’s stock.

NYSE TMO opened at $259.78 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. The firm has a market cap of $103.65 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 1.71 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 52 week low of $202.83 and a 52 week high of $282.98.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the consensus estimate of $3.19 by $0.06. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. Thermo Fisher Scientific’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.79 earnings per share. Analysts predict that Thermo Fisher Scientific Inc. will post 12.16 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th were paid a dividend of $0.19 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/thermo-fisher-scientific-inc-tmo-stake-lessened-by-rothschild-investment-corp-il.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: What are benefits of a growth and income fund?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.